Cardax devotes substantially all of its efforts to developing and commercializing safe anti inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti inflammatory without the side effects of currently marketed anti inflammatories. The safety and efficacy of Cardax s products have not been directly evaluated in clinical trials or confirmed by the FDA.
Quote | Cardax Inc (OTCMKTS:CDXI)
Last: | $1e-06 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $1e-06 |
High: | $0 |
Low: | $0 |
Volume: | 108 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Cardax Inc (OTCMKTS:CDXI)
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire HONOLULU , Aug. 11, 2021 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and...
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities PR Newswire HONOLULU , May 14, 2021 /PRNewswi...
Message Board Posts | Cardax Inc (OTCMKTS:CDXI)
Subject | By | Source | When |
---|---|---|---|
CDXI one for 200 reverse split. **PPS closed | Renee | investorshub | 01/14/2020 9:49:31 PM |
Two year low is 7 cents. Retest the low. | willlbone | investorshub | 05/21/2019 2:22:13 PM |
.0134 up selling slowed down | koolmc | investorshub | 07/16/2018 2:32:05 PM |
Nice bump today...! | Natedog69 | investorshub | 03/16/2018 6:16:04 AM |
Excellent! This is just the beginning. More international | Natedog69 | investorshub | 02/22/2018 6:11:36 AM |
News, Short Squeeze, Breakout and More Instantly...
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire HONOLULU , Aug. 11, 2021 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and...
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities PR Newswire HONOLULU , May 14, 2021 /PRNewswi...
Cardax Reports 2020 Results - Net loss and operating expenses decreased vs. 2019 - ZanthoSyn® revenues decreased vs. 2019 - Company pursuing multiple funding opportunities - CHASE study recruitment suspended due to COVID-19 - COVID-19 clinical trial grant ap...